

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Cadilla, et al.

International App. No.: PCT/US2004/018456

Group Art Unit:

International Filing Date: June 9, 2004

Examiner:

For: CHEMICAL COMPOUNDS

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
- ☒ A copy of the International Search Report which issued on International Application No. PCT/US2004/018456 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
- whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Jennifer L. Fox
Attorney for Appliant
Registration No. 52,218

Date: 8 December 05
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-6334
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PU4831USW		INTERNATIONAL APP. NO. PCT/US2004/018456	
				APPLICANT Cadilla et al.			
				INTERNATIONAL FILING DATE 6/9/04		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	1	1 086 988	10/11/67	GB			
	2	19 54 584	5/14/70	DE			
	3	03/011824	2/13/03	PCT			
	4	00/42031	7/20/00	PCT			
	5	02/24702	3/28/02	PCT			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	6	Molecules, Vol. 7, No. 12, 2002, pp. 885-895.					
	7	Chem. Pharm. Bull., Vol. 46, No. 8, 1998, pp. 1265-1273.					
	8	J. Med. Chem., Vol. 38, No. 26, 1995, pp. 5051-5065.					
	9	J. Med. Chem., Vol. , No. 8, 1995, pp. 1344-1354.					
	10	J. Med. Chem., Vol. 26, No. 10, 1983, pp. 1393-1411.					
	11	Chem. Pharm. Bull., Vol. 32, No. 10, 1984, pp. 3968-3980.					
	12	J. Pharm. Sci., Vol. 83, No. 2, 1994, pp. 219-221.					
	13	Yi-Jen Shue et al., "Direct palladium(0)-catalyzed amination of allylic alcohols with aminoaphtalenes," <u>Tetrahedron Letters</u> , V44, N7, 2/10/03, pp. 1481-1485.					
	14	Balova et al., "A one-pot synthesis of 1-arylalka-1,3-diynes by sequential acetylene zipper and Sonogashira reactions," <u>Tetrahedron Letters</u> , V44, N1, 1/1/03, pp. 107-109.					
	15	Yi Xiao and Xuhong Qian, "Novel highly efficient fluoroionophores with a peri-effect and strong electron-donating receptors: TICT-promoted PET and signaling response to transition metal cations with low background emission," <u>Tetrahedron Letters</u> , V44, N10, 2003, pp. 2087-2091.					
	16	Xuhong Qian and Yi Yiao, "4-Amino-1, 8-dicyanonaphthalene derivatives as novel fluorophore and fluorescence switches: efficient synthesis and fluorescence enhancement induced by transition metal ions and protons," <u>Tetrahedron Letters</u> , V43, N16, 2002, pp. 2991-2994.					
	17	Elslager et al., "Synthetic Schistomicides. IV. 4-Substituted 1-(Dialkylaminoalkylamino)naphthalenes," <u>J. Med. Chem.</u> V7, 1964, pp. 658-662.					
	18	<u>J. Chem., Soc.</u> , 1961, pp. 4861.					
	19	<u>J. Chem. Soc.</u> , 1964, pp. 1183.					
Continue on page 2							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.		INTERNATIONAL APP. NO.	
				APPLICANT			
				INTERNATIONAL FILING DATE		GROUP	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	20	J. Heterocycl. Chem., V31, N6, 1994, pp. 1413-1416.					
	21	J. Indian Chem. Soc., V46, 1969, pp. 115-118.					
	22	Archer et al., "4-'aminoalkyl)amino!-1, 2-dimethoxynaphthalenes as antimalarial agents," J. Med. Chem., V23, 1980, pp. 516-519.					
	23	J. Org. Chem., V37, 1972, pp. 3248-3252.					
	24	J. Med. Chem., V22, 1979, pp. 134-150.					
	25	J. Prakt. Chem., V60, N2, 1899, p. 193.					
	26	Gazz. Chim Ital., V17, 1887, p. 412.					
	27	J. Org. Chem., V. 38, 1973, pp. 2838-2842.					
	28	Phys. Chem. Chem. Phys., V2, N5, 2000, pp. 981-992.					
	29	Rec., Trav. Chem. Pays-Bas., V50, 1931, pp. 681-695.					
	30	Bartoli et al., « Reduction of Nitronate Adducts from RMgX adn 1-Methoxy-4-nitro-naphthalene to Oximes or Amines by Trivalent Phosphorus Reagents, " Tetrahedron, V. 40, N18, 1984, pp. 3437-3442.					
	31	Nigel J. Bunce and Stephen R. Cater, "Photosubstituteion of 1-Methoxy-4-nitronaphthalene with Amine Nucleophiles: Dual Pathways," J. Org. Chem., V52, 1987, pp. 4214-4223.					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							